跳至主要内容
临床试验/CTRI/2024/10/074682
CTRI/2024/10/074682尚未招募2 期

A Clinical Study on Generalized Anxiety Disorder and its Management with a Polyherbal Unani Formulation- A Randomized Standard Controlled Clinical Trial

Ayurvedic and Unani Tibbia College and Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年10月10日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
1.To assess the safety and efficacy of the proposed Unani Polyherbal Formulation in the

研究概览

简要总结

This study is a randomized, parallel group, active controlled clinical trial to evaluate the safety and efficacy of the aqueous extract form of a Unani polyherbal formulation in the management of Generalized Anxiety Disorder and to compare its efficacy with standard drug by using modern scientific parameter. The study will also be used to study the effects of the polyherbal formulation on quality of life of the patient. Anxiety disorders are among the most common of all psychiatric disorders throughout the world. An increase in global anxiety prevalence has a significant threat to the population’s well-being and quality of life. Conventional treatment for anxiety in Allopathic System of medicine include the Benzodiazepines, Antidepressants and Azapirones etc. They are useful for the short-term treatment of anxiety. However, regular long-term use carries a very high risk of tolerance and dependence. These drugs are associated with a wide range of adverse effects such as, sedation, mental confusion & weakness, impaired psychomotor performance, palpitation etc. In Unani System of Medicine, several drugs have been reported to have beneficial effects in anxiety disorders and are in clinical practice for a longer period of time. However, the safety and efficacy of these drugs have not been evaluated and documented on scientific parameters. Hence, there is a need to develop a safe, efficacious, and economical drug from the herbal treasury of Unani medicine for the treatment of Generalized Anxiety disorder.  The purpose of this study is to provide a safe, efficacious and economical drug for the management of Generalized Anxiety Disorder and to compare its efficacy with standard drug.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.Clinically diagnosed patients of Generalized Anxiety Disorder based on DSM-V criteria.
  • 2.Patients in the age group of 18 to 65 years, irrespective of gender.
  • 3.Patients, who are ready to sign the informed consent, follow the protocol and willing to participate in clinical study voluntarily.

排除标准

  • 1.Patients unwilling to sign consent.
  • 2.Patients with Anemia.
  • 3.Pregnant and lactating women.
  • 4.History of substance abuse: caffeine, alcohol, drug intoxication, smoking, tobacco chewing.
  • 5.Patients with Panic disorder, Obsessive Compulsive disorder, Post-traumatic stress disorder.
  • 6.Patients with thyroid disorders and other endocrine disorders.
  • 7.Known cases of secondary hypertension, malignancy and hepato-renal insufficiency.

结局指标

主要结局

1.To assess the safety and efficacy of the proposed Unani Polyherbal Formulation in the

时间窗: 1.To evaluate safety -Haemogram, LFT, KFT at base line, 1st week and at the end of the study. and after 6 weeks. | 2.To evaluate efficacy through assessment of subjective parameters at base line, and then weekly upto 8th week.

treatment of generalized anxiety disorder on scientific parameters.

时间窗: 1.To evaluate safety -Haemogram, LFT, KFT at base line, 1st week and at the end of the study. and after 6 weeks. | 2.To evaluate efficacy through assessment of subjective parameters at base line, and then weekly upto 8th week.

2.To compare the results of Polyherbal Unani Formulation with the standard control in the

时间窗: 1.To evaluate safety -Haemogram, LFT, KFT at base line, 1st week and at the end of the study. and after 6 weeks. | 2.To evaluate efficacy through assessment of subjective parameters at base line, and then weekly upto 8th week.

treatment of GAD in respect of safety and efficacy.

时间窗: 1.To evaluate safety -Haemogram, LFT, KFT at base line, 1st week and at the end of the study. and after 6 weeks. | 2.To evaluate efficacy through assessment of subjective parameters at base line, and then weekly upto 8th week.

次要结局

  • To evaluate the effects of Unani Polyherbal Formulation on the Quality of life of the patient(of GAD.)

研究者

发起方
Ayurvedic and Unani Tibbia College and Hospital
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Shumaila saifi

Ayurvedic and Unani Tibbia College and Hospital

研究点 (1)

Loading locations...

相似试验

To compare the effects of a polyherbal Unani... | 临床试验